- Industry veteran to build on AiCure's ten years of market success and extend 
AI platform to digital biomarkers for holistic patient health

- Continued corporate growth and platform milestones drive 2020 momentum

AiCure ( 
https://c212.net/c/link/?t=0&l=en&o=2787735-1&h=3494405458&u=http%3A%2F%2Fwww.aicure.com%2F&a=AiCure 
), an AI and advanced data analytics company focused on improving clinical 
trials, today announced Ed Ikeguchi, M.D. as its Chief Executive Officer (CEO). 
Formerly serving as the company's Chief Medical Officer (CMO) and President, 
Dr. Ikeguchi's appointment as CEO will advance AiCure's commitment to improving 
holistic health through an understanding of the science behind human responses 
to illness and treatment. With today's announcement ( 
https://c212.net/c/link/?t=0&l=en&o=2787735-1&h=1422592979&u=https%3A%2F%2Faicure.com%2Faicure-industry-first-computer-vision-to-capture-dbm%2F&a=today%27s+announcement 
) of digital biomarkers, AiCure is delivering on this vision.

Logo - https://mma.prnewswire.com/media/1022858/AiCure_Logo.jpg 

Prior to joining as AiCure's CMO in 2018, Dr. Ikeguchi co-founded Medidata 
Solutions, where he grew the company from its inception to its initial public 
offering in 2009 while serving as its CEO from 1999-2001 and its CMO from 
2001-2009. Dr. Ikeguchi's extensive experience in both the C-suite and in 
clinical environments, including his understanding of the many pain points of 
patient engagement, positions him well to lead the company in its next phase. 

Dr. Ikeguchi takes the helm of AiCure, which for ten years, has enhanced the 
quality of clinical trial data by providing real-time monitoring of patient 
dosing and behavior, enabling smaller, faster trials. AiCure has established 
its value to pharmaceutical companies and healthcare organizations by providing 
novel insights into patient behavior, allowing them to measure and modify it 
for optimal care. Capitalizing on the wealth of behavioral data AiCure has 
stored and analyzed, Dr. Ikeguchi will expand the company's footprint in 
digital biomarking to identify non-obvious patient reactions to capture a 
complete picture of complex human behavior. Further equipping clients with an 
understanding of such behavioral trends will empower real-time, objective 
observations of people in their natural environment that can help improve 
patient and trial outcomes.

"The traditional brick-and-mortar blueprint of healthcare and clinical trials 
only lends itself to transactional patient relationships and blind spots 
between in-person visits. At AiCure, we aim to shift this mindset and achieve 
continuous line-of-sight into an individual's wellbeing," said Dr. Ed Ikeguchi, 
CEO of AiCure. "It is my privilege to lead the company in its next chapter as 
we work toward holistic health delivery, deepen our understanding of patients' 
lived experience, and elevate the credibility of clinical trial results. We are 
poised to build on our strong momentum and further make our mark in patient 
care and drug development."

Pillars of Success Drive 2020 Growth

In addition to Dr. Ikeguchi's appointment, AiCure has achieved several 
milestones for a strong 2020 performance to-date, including:  

    -- Sustained corporate momentum: 
        -- Addition of Vidhi Goel as the new vice president of marketing, 
           leveraging her two decades of industry experience to address 
           customer needs 
        -- Continued revenue growth across both new clients and repeat 
           business from top-20 pharma companies, including 200% growth in 
           digital biomarker customers 
        -- Ongoing collaborations with sponsors to develop predictive 
           analytics to build industry-leading tools for monitoring 
           participant and site performance

    -- Expansion of platform: 
        -- Official launch of the company's first digital biomarker platform 
           to remotely detect subtle changes in a patient's condition 
        -- New caregiver functionality that allows for notifications and text 
           alerts to be shared with approved caregivers to enhance the 
           platform's use in pediatric trials and for conditions like 
           Parkinson's and Alzheimer's Disease 
        -- Introduction of home visit workflow to support in-home nurse
           visits, reducing the need for a patient to go into a clinic 
        -- New electronic patient reported outcome (ePRO) capabilities 
           that increase patient engagement and aim to replicate traditional 
           clinician assessments

    -- Improved technology features: 
        -- Enhanced video review capabilities to better monitor for 
           intentional non-adherence in high-risk studies 
        -- Deployment of single sign-on capability and availability of 
           the platform in four additional languages, bringing total 
           availability to 45 languages 
        -- Expanded analytics engine to extend continuous learning 
           capabilities of machine learning platform 
        -- Customized reporting that analyzes customer study performance 
           against industry benchmarks. 

About AiCure 
AiCure is an AI and advanced data analytics company that monitors patient 
behavior and enables remote patient engagement in clinical trials. AiCure 
improves predictability of study timelines, reduces costs and accelerates 
timelines through remote patient engagement and assessments, including 
measuring digital biomarkers and real-time monitoring of patient dosing. 
Founded in 2010 and funded by the National Institutes of Health (NIH) and 
leading institutional investors, AiCure has more than 65 issued patents and 
works with global clients in over 30 countries. AiCure is globally recognized 
and is a recipient of the Scrip Award, AI 100 and Digital Health 150. For more 
information, please visit www.aicure.com.   

Media Contact 
Siobhan Nguyen 
aicure@fleishman.com 
+1-617-986-5784

SOURCE:  AiCure